Analysts’ Weekly Ratings Changes for Bioverativ (BIVV)

Several brokerages have updated their recommendations and price targets on shares of Bioverativ (NASDAQ: BIVV) in the last few weeks:

  • 1/24/2018 – Bioverativ had its “hold” rating reaffirmed by analysts at Argus.
  • 1/24/2018 – Bioverativ had its “neutral” rating reaffirmed by analysts at Credit Suisse Group AG.
  • 1/23/2018 – Bioverativ was downgraded by analysts at Raymond James Financial, Inc. from a “strong-buy” rating to a “hold” rating.
  • 1/23/2018 – Bioverativ was upgraded by analysts at Morgan Stanley from an “underweight” rating to an “equal weight” rating.
  • 1/22/2018 – Bioverativ was downgraded by analysts at Jefferies Group LLC from a “buy” rating to a “hold” rating.
  • 1/22/2018 – Bioverativ was downgraded by analysts at Piper Jaffray Companies from an “overweight” rating to a “neutral” rating.
  • 1/18/2018 – Bioverativ had its price target raised by analysts at Royal Bank of Canada to $68.00. They now have a “market perform” rating on the stock.
  • 1/18/2018 – Bioverativ had its “neutral” rating reaffirmed by analysts at Credit Suisse Group AG. They now have a $65.00 price target on the stock.
  • 1/18/2018 – Bioverativ had its price target raised by analysts at Jefferies Group LLC to $79.00. They now have a “buy” rating on the stock.
  • 1/8/2018 – Bioverativ was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $62.00 price target on the stock. According to Zacks, “Bioverativ Inc. is a biotechnology company. It focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. Bioverativ Inc. is based in Waltham, United States. “
  • 1/3/2018 – Bioverativ was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Bioverativ Inc. is a biotechnology company. It focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. Bioverativ Inc. is based in Waltham, United States. “
  • 1/1/2018 – Bioverativ was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $60.00 price target on the stock. According to Zacks, “Bioverativ Inc. is a biotechnology company. It focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. Bioverativ Inc. is based in Waltham, United States. “

Shares of Bioverativ Inc (BIVV) opened at $103.60 on Tuesday. Bioverativ Inc has a 52 week low of $43.19 and a 52 week high of $104.30.

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply